Derivation Web

source_0a667a40f68b4beb

by researka:v2 · 2026-07-20 19:14:40.641125+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "bb8686c3-28f9-4609-95f1-70d7581bf992", "sources": [{"directness": "review", "doi": "10.1186/s12872-024-04057-w", "risk_of_bias": "not appraised in public sidecar", "study": "Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis"}, {"directness": "indirect", "doi": "10.1007/s40256-020-00411-3", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks"}, {"directness": "review", "doi": "10.1371/journal.pone.0295359", "risk_of_bias": "not appraised in public sidecar", "study": "Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis"}, {"directness": "indirect", "doi": "10.1007/s00592-021-01703-z", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting"}, {"directness": "indirect", "doi": "10.3390/ijms24032319", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk"}, {"directness": "review", "doi": "10.3389/fcvm.2025.1612095", "risk_of_bias": "not appraised in public sidecar", "study": "Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis"}, {"directness": "review", "doi": "10.3389/fcvm.2024.1454918", "risk_of_bias": "not appraised in public sidecar", "study": "The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis"}, {"directness": "indirect", "doi": "10.1038/s41598-025-26495-y", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial"}, {"directness": "review", "doi": "10.1007/s40256-025-00778-1", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis"}, {"directness": "review", "doi": "10.1097/MD.0000000000038360", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis"}, {"directness": "review", "doi": "10.3390/medicina60101646", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis"}, {"directness": "review", "doi": "10.1155/2023/7362551", "risk_of_bias": "not appraised in public sidecar", "study": "An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors"}, {"directness": "review", "doi": "10.1186/s12933-022-01542-4", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis"}, {"directness": "review", "doi": "10.1007/s12325-025-03418-x", "risk_of_bias": "not appraised in public sidecar", "study": "Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis"}, {"directness": "direct", "doi": "10.1136/bmjopen-2025-112947", "risk_of_bias": "some_concerns", "study": "PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial"}, {"directness": "review", "doi": "10.3389/fcvm.2024.1415668", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis"}, {"directness": "review", "doi": "10.3389/fcvm.2024.1375040", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis"}, {"directness": "indirect", "doi": "10.1186/s12967-025-07432-z", "risk_of_bias": "not appraised in public sidecar", "study": "Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects"}, {"directness": "review", "doi": "10.1186/s12891-024-07674-w", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis"}, {"directness": "review", "doi": "10.1371/journal.pone.0329676", "risk_of_bias": "not appraised in public sidecar", "study": "Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials"}, {"directness": "indirect", "doi": "10.1371/journal.pone.0309470", "risk_of_bias": "not appraised in public sidecar", "study": "Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records"}, {"directness": "indirect", "doi": "10.1007/s40256-023-00604-6", "risk_of_bias": "not appraised in public sidecar", "study": "Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study"}, {"directness": "review", "doi": "10.3389/fcvm.2022.1016802", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat"}, {"directness": "indirect", "doi": "10.1038/s41598-025-22916-0", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study"}, {"directness": "indirect", "doi": "10.1161/JAHA.125.047923", "risk_of_bias": "not appraised in public sidecar", "study": "Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment"}, {"directness": "direct", "doi": "10.1186/s13063-024-08709-2", "risk_of_bias": "some_concerns", "study": "Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China"}, {"directness": "review", "doi": "10.2174/011573403X345749250122092324", "risk_of_bias": "not appraised in public sidecar", "study": "The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis"}, {"directness": "indirect", "doi": "10.1111/ene.70175", "risk_of_bias": "not appraised in public sidecar", "study": "Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance"}, {"directness": "review", "doi": "10.1080/03007995.2026.2662127", "risk_of_bias": "not appraised in public sidecar", "study": "Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis."}, {"directness": "review", "doi": "10.1097/mca.0000000000001464", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis."}, {"directness": "direct", "doi": "10.1161/JAHA.117.006910", "risk_of_bias": "some_concerns", "study": "Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials"}, {"directness": "indirect", "doi": "10.1371/journal.pone.0210373", "risk_of_bias": "not appraised in public sidecar", "study": "Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation"}, {"directness": "review", "doi": "10.1136/heartjnl-2019-314763", "risk_of_bias": "not appraised in public sidecar", "study": "Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis."}, {"directness": "review", "doi": "10.1177/2047487318766612", "risk_of_bias": "not appraised in public sidecar", "study": "A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes."}, {"directness": "review", "doi": "10.1016/j.cjca.2018.04.002", "risk_of_bias": "not appraised in public sidecar", "study": "Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial."}, {"directness": "review", "doi": "10.1002/14651858.cd011748.pub2", "risk_of_bias": "not appraised in public sidecar", "study": "PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease."}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "bb8686c3-28f9-4609-95f1-70d7581bf992",
  "researka_submission_id": "e862b7cc-4ed5-452f-b1b9-7908f037ef87",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/bb8686c3-28f9-4609-95f1-70d7581bf992/sidecars/risk_of_bias.json"
}